Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

被引：0
|
作者：
Kohei Shitara
Hiroki Hara
Takaki Yoshikawa
Kazumasa Fujitani
Tomohiro Nishina
Ayumu Hosokawa
Takashi Asakawa
Satoe Kawakami
Kei Muro
机构：
[1] National Cancer Center Hospital East,Gastroenterology and Gastrointestinal Oncology
[2] Saitama Cancer Center,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[4] National Cancer Center Hospital,Department of Gastric Surgery
[5] Osaka General Medical Center,Department of Surgery
[6] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[7] University of Toyama,Department of Gastroenterology and Hematology, Faculty of Medicine
[8] University of Miyazaki Hospital,Department of Clinical Oncology
[9] Chugai Pharmaceutical Co.,Clinical Information and Intelligence Department
[10] Ltd,Clinical Science & Strategy Department
[11] Chugai Pharmaceutical Co.,Department of Clinical Oncology
[12] Ltd,undefined
[13] Aichi Cancer Center Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pertuzumab; Trastuzumab; Metastatic gastric cancer; Metastatic gastroesophageal junction cancer; Japanese subgroup analysis; Phase III;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 311
页数：10
相关论文
共 50 条
  • [21] Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.
    Rha, Sun Young
    Revil, Cedric
    Valderrama, Adriana
    Wang, Liya
    Andre, Manon
    McCarthy, Grant
    Young, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 354 - 354
  • [22] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [23] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [24] End-of-study analysis from JACOB: A phase III study of pertuzumab (P) plus trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
    Tabernero, J.
    Hoff, P. M.
    Shen, L.
    Ohtsu, A.
    Shah, M. A.
    Siddiqui, A.
    Heeson, S.
    Wu, H.
    Restuccia, E.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2020, 31 : S900 - S901
  • [25] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
    Roviello, Giandomenico
    Generali, Daniele
    LANCET ONCOLOGY, 2018, 19 (10): : 1270 - 1272
  • [27] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [28] First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
    Esen, Selin Akturk
    Ergun, Yakup
    Erol, Cihan
    Arikan, Rukiye
    Er, Muhammed Muhiddin
    Atci, Muhammed Mustafa
    Topcu, Atakan
    Ucar, Gokhan
    Akagunduz, Baran
    Aykan, Musa Baris
    Ozen, Mirac
    Baytemur, Naziyet Kose
    Ozcelik, Melike
    Sahin, Elif
    Guven, Denizcan
    Menekse, Serkan
    Ak, Naziye
    Teker, Fatih
    Kut, Engin
    Sakalar, Teoman
    Alan, Ozkan
    Kacan, Turgut
    Turhal, Nazim Serdar
    Kilickap, Saadettin
    Turker, Sema
    Sendur, Mehmet Ali Nahit
    Kostek, Osman
    Karaagac, Mustafa
    Sakin, Abdullah
    Turk, Haci Mehmet
    Caglayan, Dilek
    Cihan, Sener
    Acikgoz, Yusuf
    Uncu, Dogan
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 22 (05) : 818 - 825
  • [29] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
    Printz, Carrie
    CANCER, 2020, 126 (09) : 1827 - 1827
  • [30] HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) plus trastuzumab (T) plus /- pertuzumab (P) in the JACOB trial
    Pietrantonio, F.
    Berrino, E.
    Manca, P.
    Bellomo, S. E.
    Raimondi, A.
    Corso, S.
    Morano, F.
    Migliore, C.
    Niger, M.
    Marchio, C.
    Di Bartolomeo, M.
    Restuccia, E.
    Lambertini, C.
    Tabernero, J.
    Giordano, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1100 - S1101
12345